Long-term results of catheter ablation for atrial fibrillation in 866 patients

Martin Fiala\textsuperscript{a,b,*}, Libor Škňouřil\textsuperscript{a}, Ondřej Toman\textsuperscript{b}, Jakub Pindor\textsuperscript{a}, Veronika Bulková\textsuperscript{a}, Jan Chovančík\textsuperscript{a}, Radek Neuwirth\textsuperscript{a}, Růžena Lábrová\textsuperscript{b}, Jaroslav Januška\textsuperscript{a}, Jindřich Špína\textsuperscript{b}

\textsuperscript{a}Department of Cardiology, Hospital Podlesí a.s., Třinec, Czech Republic
\textsuperscript{b}Department of Cardiology and Internal Medicine, Faculty Hospital and Masaryk University, Brno, Czech Republic

ARTICLE INFO

Article history:
Received 23 September 2012
Received in revised form
30 October 2012
Accepted 31 October 2012
Available online 9 November 2012

Keywords:
Atrial fibrillation
Catheter ablation
Recurrent arrhythmias
Outcome

ABSTRACT

Purpose: This study presents eight-year experience with ablation techniques, recurrent arrhythmias, and long-term outcomes in patients undergoing catheter ablation for atrial fibrillation (AF).

Methods: Catheter ablation of AF was performed in 866 consecutive patients in a total of 1272 ablation procedures. Ablation strategy and procedure endpoints were left at the operator's discretion. Total study population and groups of paroxysmal (n=508/59%), persistent (n=102/12%), and long-standing persistent AF (n=256/29%) were evaluated.

Results: Pulmonary vein isolation alone or with cavo-tricuspid isthmus ablation was accomplished in 36% of the patients. It was significantly more often used in paroxysmal AF than in persistent or long-standing persistent AF (both \( p < 0.001 \)). More extensive ablation prevailed in persistent AF types. Ablation was repeated in 307 (35%) patients. Patients with long-standing persistent AF underwent significantly more repeat procedures than patients with paroxysmal AF (\( p < 0.001 \)) or persistent AF (\( p = 0.001 \)). Recurrent AF dominated before the first repeat ablation in 68% cases, while recurrent atrial tachycardia (AT) prevailed before the second (73%), and third (93%) repeat ablation. Patients with long-standing persistent AT presented with recurrent AF in 50% of the cases already before the first repeat ablation. At the end of 49.72 months follow-up, 83% of the patients remained in stable sinus rhythm (SR); 70% of the patients without antiarrhythmic drugs. SR maintenance was insignificantly superior in long-standing persistent AF group (91%) compared to paroxysmal AF (82%) and persistent AF patients (68%).

Conclusion: Patients with persistent AF types underwent more extensive initial ablation. Patients with long-standing persistent AF experienced best long-term outcome likely as a consequence of higher number of repeat ablation procedures.

© 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z.o.o. All rights reserved.

1. Introduction

Catheter ablation can effectively cure atrial fibrillation (AF), yet, early as well as late arrhythmia recurrences occur and multiple procedures of different extent may be required to eventually restore stable sinus rhythm (SR) [1–4]. Although in theory absolutely effective, AF ablation in routine clinical practice still remains limited to a selected population of

*Correspondence to: Department of Cardiology, Heart Center Hospital Podlesí a.s. Konšká 453, Třinec 739 61, Czech Republic.
Tel.: +420 5583 04451; fax: +420 5583 04457.
E-mail address: martin.fiala@gmail.com (M. Fiala).

0010-8650/ - see front matter © 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z.o.o. All rights reserved.
http://dx.doi.org/10.1016/j.crvasa.2012.10.006
patients with variable center- and operator-related outcomes [5].

This retrospective study analyzed ablation techniques, recurrent arrhythmias, and long-term ablation outcomes in consecutive patients who underwent ablation procedure for AF within a period of eight years.

2. Methods

2.1. Patient population

The study included 866 consecutive patients, who underwent catheter ablation for symptomatic AF between June 2003 and June 2011. These patients underwent a total of 1272 ablation procedures for AF or residual atrial tachycardia (AT). Repeat procedures were accomplished by the end of September 2011. First ablation was performed in the main study center, while for later working restraints in this center some of the repeat ablations had to be performed in the second study center. Follow-up was closed on December 31, 2011, so that the minimum follow-up period amounted to 6 months since the first ablation, and 3 months since the last ablation, respectively. The study population was distributed into three groups of patients with paroxysmal (n=508/59%), persistent (n=102/12%), and long-standing persistent AF (n=256/29%). Baseline characteristics are summarized in Table 1.

2.2. Ablation procedure and pre-ablation and post-ablation management

The details about ablation techniques and pre-ablation and post-ablation management were described previously [6–9]. Briefly, warfarin was discontinued and replaced by low-molecular-weight heparin for 5 days prior to ablation. Laboratory tests were performed before the ablation procedure to exclude thrombus and to obtain other parameters. Antiarrhythmic drugs (AADs) were often continued throughout the procedure in the early stages of our ablation practice, while there was tendency to discontinue AADs before ablation in the later years.

For the ablation procedure, a 10-pole catheter (Daig, St. Jude, Minnetonka, MN, USA) was positioned in the coronary sinus (CS), and a 10-pole ring catheter (Lasso, Biosense Webster, Diamond Bar, CA, USA) and a mapping/ablation catheter (ThermoCool or NaviStar ThermoCool, Biosense Webster) were inserted via two 8 F transseptal sheaths (Daig, St. Jude) in the left atrium (LA) and pulmonary veins (PVs). Heparin was given to maintain activated clotting time (ACT) between 250–350 s in the first years, and 300–400 s in the later years. Bipolar endocardial electrograms were filtered at a band-pass setting of 30–500 Hz and displayed at 200 mm/s speed (CardioLab System, Prucka Engineering, Sugar Land, TX, USA). A few early ablation procedures were performed conventionally without using 3-dimensional non-fluoroscopic mapping, while a majority of ablation procedures were guided by 3-dimensional electroanatomic left atrial (LA) and possibly right atrial (RA) mapping (CARTO system), (Biosense Webster). Radiofrequency energy was applied with a Stockert generator (Biosense Webster). The power and temperature limits evolved over time to finally use irrigation of 17–30 ml/min (heparinized 0.9% saline) and temperature and power limits of 42 °C and 35 W (limited to 20 ml/min and 20–25 W inside the CS) in the last 5 years.

The extent of ablation strategy and procedure endpoints differed among the patients; however, full PV isolation validated by the ring catheter was the mandatory procedure endpoint in all patients. Patients with long-standing persistent AF invariably received extensive ablation consisting minimally of the mandatory wide-area PV isolation and LA roof and mitral isthmus linear lesions; AF termination and SR restoration by radiofrequency applications were always pursued as an ideal procedure endpoint. Converted AT, macroreentry or localized, was characterized according to standard criteria and identified by the means of activation and entrainment mapping [10].

Heparin was stopped at the end of the procedure, and low-molecular-weight heparin was administered until warfarin reached full therapeutic effect. Warfarin was stopped following a minimum of 6 weeks after uncomplicated PV isolation for paroxysmal AF up to 6 months after complex ablation for persistent AF in case of stable SR, preserved LA appendage outflow velocity (generally ≥40 cm/s), and no other conditions favoring permanent anticoagulation. In the later years, there was a tendency to avoid re-initiation of AADs; however, they were sometimes resumed to stabilize SR in the early post-ablation course.

2.3. Follow-up

Patients were seen at the outpatient department after 6 weeks, 3, 6, 9, and 12 months, and then every 6 months in

Table 1 – Baseline Characteristics in Total and in Groups by AF Type.

<table>
<thead>
<tr>
<th></th>
<th>Total (n=866)</th>
<th>Paroxysmal AF (n=508)</th>
<th>Persistent AF (n=102)</th>
<th>LS Persistent AF (n=256)</th>
<th>p Parox-LS</th>
<th>p Parox-Pers</th>
<th>p Pers-LS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Females</td>
<td>238 (27%)</td>
<td>153 (30%)</td>
<td>27 (26%)</td>
<td>58 (23%)</td>
<td>0.583</td>
<td>0.097</td>
<td>0.550</td>
</tr>
<tr>
<td>Age (years)</td>
<td>57±10</td>
<td>56±10 (21–82)</td>
<td>61±9 (32–78)</td>
<td>58±9 (24–79)</td>
<td>&lt;0.001</td>
<td>0.056</td>
<td>0.009</td>
</tr>
<tr>
<td>CHADS₂ score</td>
<td>1.2±1.0</td>
<td>1.1±1.0 (0–5)</td>
<td>1.3±0.8 (0–4)</td>
<td>1.3±0.9</td>
<td>0.028</td>
<td>&lt;0.001</td>
<td>0.792</td>
</tr>
<tr>
<td>LA diameter (mm)</td>
<td>44±6</td>
<td>42±5 (25–61)</td>
<td>46±7 (29–76)</td>
<td>48±5 (33–68)</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>0.003</td>
</tr>
<tr>
<td>LV EF (%)</td>
<td>57±7</td>
<td>59±5 (35–72)</td>
<td>56±8 (25–65)</td>
<td>54±9 (20–67)</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>0.028</td>
</tr>
</tbody>
</table>

AF = atrial fibrillation; LA = left atrial; LS = long-standing; LV EF = left ventricular ejection fraction; Parox = paroxysmal; Pers = persistent.
the first post-ablation years. Patient with stable SR long-term were later periodically contacted over phone. ECG documentation consisted of 12-lead ECG recordings at every visit and interim visits at local cardiologists and 24-h ECG recordings several times a year. In multiple patients, a 2-3-week transtelephonic ECG monitoring with loop-recorder every six months was employed, while many others received an episodic recorder for daily many ECG recordings, both random and during symptoms for up to one-year period. Arrhythmia recurrence included ECG documented AF/AT, and also any history of palpitations suggestive of AF/AT lasting >30 s.

2.4. Data presentation

The outcomes are presented in total and separately for the three standard AF types (paroxysmal, persistent, and long-standing persistent) according to the current consensus for AF treatment [11]. Variability in the arrhythmogenic substrates with wide overlap among the AF types individualized ablation strategy. Further, ablation strategy varied depending on the operator’s discretion, individual skill/learning curve, and/or preset protocols of studies, in which some of the patients were included. Finally, radiofrequency energy settings and follow-up density varied due to natural evolution of the method and means of ECG monitoring available. Therefore, for the purpose of this retrospective analysis, categorization of the presented data had to be simplified.

Ablation extent was distributed into 5 categories: (1) PV isolation (PV encircling with isolation only); (2) PV isolationþcavo-tricuspid isthmus (CTI) ablation; (3) LA ablation (PV isolationþpossible CTI ablationþdifferent extent of additional LA ablation outside PVs in terms of linear and/or electrogram-guided ablation; (4) LA ablationþCS ablation (CS ablation might include limited distal CS ablation to finalize mitral isthmus conduction block, or full CS isolation that eliminated a localized AF sources within the CS, or was performed during AF ongoing after extensive LA ablation); and (5) LA ablation (+CS ablation)+RA ablation (RA ablation might include inter-caval line and/or electrogram-guided ablation).

Recurrent arrhythmias were classified into (1) paroxysmal AF; (2) persistent AF; (3) paroxysmal AT; and (4) persistent AT. If the patient presented with recurrent AT, a single AT type versus ≥2 AT types were differentiated by the means of invasive mapping. AT decelerated by prior radiofrequency energy application, or macroreentry AT rotating alternately in both directions was still considered one distinct AT type.

Final ablation outcome was shown as (1) SR maintenance with/without AADs; (2) SR maintenance without AADs; (3) Recurrences of paroxysmal AF/AT; and (4) Recurrence of persistent AF/AT.

2.5. Statistical analysis

Continuous variables were expressed as mean±standard deviation and compared by the 2-tailed Student’s t-test for independent samples. Categorical variables were expressed as percentages and compared by χ²-test. Arrhythmia-free survival in the respective groups was compared by Kaplan–Meier survival analysis with log-rank test. A p value <0.05 was considered significant. STATISTICA vers.6.1 (Statsoft, Inc.) was used for the analysis.

3. Results

3.1. Initial ablation extent

PV isolation alone or with CTI ablation was accomplished in 36% of the patients. It was significantly more often performed in patients with paroxysmal AF than in patients with persistent or long-standing persistent AF (both p<0.001). More extensive LA ablation was employed in another 38% of the patients; significantly more often in patients with persistent AF compared to paroxysmal AF (p<0.001) or long-standing persistent AF (p=0.002), while there was no difference between the latter two groups (p=0.464). LA ablation+CS ablation, or LA (+CS ablation)+RA ablation were performed in another 16% and 9% patients, respectively. LA ablation+CS ablation was more frequently performed in both persistent AF groups than in paroxysmal AF patients (both p<0.001); there was no difference between persistent and long-standing persistent AF groups (p=0.168). Finally, LA ablation (+CS ablation)+RA ablation was significantly more often carried out in patients with long-standing persistent AF compared to paroxysmal or persistent AF patients (both p<0.001) (Fig. 1).

3.2. Repeat ablation

The 866 patients underwent a total of 1272 ablation procedures (1.5 procedure/patient). A single ablation was performed
in 559 (65%) patients, while ablation was repeated in 307 (35%) patients. Two and three repeat ablation procedures were performed in 71 (8%) and 14 (2%) patients, respectively. Patients with long-standing persistent AF underwent two ablation procedures more often than patients with paroxysmal AF (p<0.001) or persistent AF (p=0.001). Similarly, they more frequently underwent three ablation procedures (p<0.001 for comparison with paroxysmal AF group, and p=0.013 for comparison with persistent AF group). There were no significant differences between paroxysmal and persistent AF patients in the counts of two (p=0.678) or three (p=0.728) ablation procedures (Fig. 2).

3.3. Ablation procedure characteristics

Procedure, fluoroscopy, and radiofrequency delivery times of all 1272 ablation procedures were 272±81 (60–600), 29±16 (5–105), and 92±41 (5–242) min, respectively. Respective times in different AF groups are compared in Table 2. Procedure time in paroxysmal AF group was significantly shorter than the time in persistent AF groups. On the contrary, fluoroscopy time in the long-standing persistent AF group was significantly shorter than in the other groups.

3.4. Recurrent arrhythmias

The spectrum of recurrent arrhythmias evolved with the number of repeat ablation procedures, and also depended on the AT type/extent of ablation strategy. AF dominated before the first repeat ablation in 68% of the cases (paroxysmal AF—41%, persistent/long-standing persistent AF—27%), while AT prevailed before the second (73%), and third (93%) repeat ablation (Fig. 3). There was a clear tendency to more frequent

![Fig. 2 – Repeat ablation procedures in different AF groups. Patients with long-standing (LS) persistent AF underwent significantly more repeat (first repeat and second repeat) ablation procedures.](image)

![Fig. 3 – Proportions of different types of recurrent arrhythmia in all patients undergoing repeat ablation procedures. Atrial fibrillation (AF) prevailed before the first repeat ablation, atrial tachycardia (AT) represented dominant recurrent arrhythmia before second and third repeat ablation. Parox = paroxysmal, Pers = persistent.](image)

<table>
<thead>
<tr>
<th>Table 2 – Ablation Procedure Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>--------------------------------------------</td>
</tr>
<tr>
<td>Procedure time (min)</td>
</tr>
<tr>
<td>Fluoroscopy time (min)</td>
</tr>
<tr>
<td>RF delivery time (min)</td>
</tr>
</tbody>
</table>

AF=atrial fibrillation; LS=long-standing; Par=paroxysmal; Pers=persistent; Pers-LS=long-s persistent; RF=radiofrequency energy.
AT recurrence already before the first repeat ablation in long-standing persistent AF group (50%) or persistent AF group (35%) when compared with paroxysmal AF group (14%) \((p<0.001\) for comparison between long-standing and paroxysmal AF; \(p=0.041\) for comparison between persistent and paroxysmal AF; \(p=0.372\) for comparison between persistent and long-standing persistent AF) (Fig. 4).

Persistent AF/AT prevailed after ablation of primary persistent (in 77% of the cases; \(p=0.002\)) or long-standing persistent AF (in 83% of the cases; \(p<0.001\)) compared with paroxysmal AF group, in which persistent AF/AT recurred after the initial ablation in only 27% of the cases (Fig. 4).

A single AT versus \(\geq 2\) ATs were present before repeat ablation in 65 versus 108 cases, respectively. Presence of \(\geq 2\) ATs dominated over single AT in all three ablation groups (35 versus 12 in paroxysmal AF group, 10 versus 3 in persistent AF group, and 63 versus 50 in long-standing persistent AF group).

### 3.5 Long-term outcome

Ten (1%) patients (mean age 61±12, range 34–78 years) died \(31±19\) (5–60) months after the last ablation. These patients belonged to the groups of paroxysmal (0.8%), persistent (0.9%), and long-standing persistent AF (2%). The cause of death was cancer in 4 patients, cerebral hemorrhage while taking warfarin with international normalized ratio within the range 2–3 in 2 patients, aortic dissection in 1 patient, infective endocarditis as a resistant complication of later pacemaker implantation in 1 patient, heart failure due to recurrent myocardial infarction in 1 patient, and motorcycle accident in 1 young patient. In addition, 1(0.1%) patient with paroxysmal AF died in the year 2005 of fulminant cardiac tamponade that developed 26 h after the first ablation procedure.

Kaplan–Meier curves of arrhythmia-free survival after the initial (A) and the last ablation procedure (B).

At the end of \(49±26\) (6–102) month total follow-up time, and \(41±26\) (3–102) month follow-up period since the last ablation, 717 (83%) patients were in stable SR; 605 (70%) patients did not use class I or III AAD. Paroxysmal or persistent AF/AT recurrences continued in 101 (12%) and 48 (5%) patients, respectively. SR maintenance was insignificantly superior in long-standing persistent AF patients [233 (91%) patients] compared to paroxysmal AF patients [415 (82%) patients] \((p=0.335)\). On the contrary, the worst outcome was observed in the group of persistent AF [69 (68%) patients in SR] \((p=0.264\) for comparison with paroxysmal AF; \(p=0.099\) for comparison with long-standing persistent AF) (Fig. 6).

Warfarin use in 810 (94%) patients before ablation was reduced to 269 (31%) patients at the end of the follow-up.
performed in 51% of the patients and was dominating ablation strategy in treatment of paroxysmal AF; (2) Complex ablation strategies at the initial procedure prevailed in persistent/long-standing persistent AF; (3) Repeat ablation was most often performed in the group of long-standing persistent AF; (4) Recurrent AT begun to prevail after the first repeat ablation, however, constituted half of the recurrent arrhythmias already after the initial extensive ablation for long-standing persistent AF; (5) Best final long-term maintenance of SR was achieved in the long-standing persistent AF group.

4.1. Ablation extent

The extent of initial ablation strategy largely depended on the preset procedure endpoints. In general, extensive extra-PV ablation was more often required in persistent/long-standing persistent AF patients, in whom AF termination and SR restoration by mere radiofrequency energy applications were pursued as the procedural endpoint of initial ablation. On the other hand, procedure endpoints markedly varied in paroxysmal AF patients. In some of these patients, simple PV isolation was considered a sufficient initial procedure endpoint [8]. In many others, in case of ongoing arrhythmia following PV isolation, efforts to restore SR by extra-PV LA/CS ablation were made. In addition, it was left at the operator’s discretion, whether arrhythmia noninducibility was tested by incremental atrial pacing and/or pharmacological provocation with isoproterol and adenosine following PV isolation, and whether it was further pursued in case of AF/AT re-induction. Hence, even in some paroxysmal AF patients, localized AF/AT sources outside the PVs and/or residual macroreentry AT were further targeted.

4.2. Recurrent arrhythmias and repeat ablation

A noticeable disparity was observed between the recurrent arrhythmias after the initial ablation of paroxysmal, persistent, or long-standing persistent AF, respectively. Long-standing persistent AF patients presented with recurrent AT in half of the cases already after the initial ablation, clearly as a consequence of extensive ablation rendering the atria incapable of further disorganized fibrillatory activity. Although these ATs were often labeled as an unwanted proarrhythmic effect [12,13], they frequently represent rather unmasked residual arrhythmia easier to re-ablate than recurrent AF [14]. Many of these ATs originated from a localized source likely existing prior to any ablation as a “background” AF driver that was unmasked and could be mapped selectively only after the initial extensive ablation [15]. Repeat ablation increased the proportion of recurrent ATs also in the paroxysmal AF group, so that the AT dominated before the second or third repeat ablation in all the groups.

Typically, following ablation of persistent/long-standing persistent AF, again persistent AF/AT recurred, while paroxysmal arrhythmia (mainly AF) dominated after ablation of paroxysmal AF. It may have important clinical implications for identification of recurrent arrhythmias. In appears that a majority of persistent AF/AT after ablation of persistent AF types can be revealed by means of standard follow-up with low risk of missing asymptomatic AF/AT episodes. Correlation
of standard follow-up with longer-term ECG monitoring after ablation of long-standing persistent AF proved (unlike paroxysmal AF) very low incidence of clinically unrecognized AF/AT recurrences (data not shown).

AF substrate and sources are generally more complex in persistent AF and usually progress with the duration of persistent AF phase. Consequently, initial ablation strategy is commonly extensive, and the need for repeat ablation procedures is larger [16–18]. However, there are several facts that might overestimate the contrast in the number of repeat ablation procedures between patients with long-standing persistent AF and other AF types. First, patients with long-standing persistent AF were mostly ablated in prospective studies. To achieve ideal outcomes, they were frequently offered a repeat ablation even after several isolated AT episodes that might have been suppressible by AADs. On the other hand, in many paroxysmal AF patients, reduction in the AF/AT burden was occasionally tolerated as good arrhythmia control, and repeat ablation was not urged. Second, 26 patients with paroxysmal AF (compared to none with long-standing persistent AF) previously underwent AF ablation in another center that was not calculated in this analysis. Including these ablation procedures, the proportion of paroxysmal AF patients with repeat ablation would increase from 28% to 33%. Further, in separate studies, we have observed improved outcomes of a single ablation for long-standing AF as our experience increased. To achieve similar outcomes, repeat ablation was required in only 43% out of the last 80 patients, while it was needed in more than 60% of the preceding 100 patients. Therefore, outcome of extensive ablation for persistent or long-standing persistent AF is likely to improve with experience, and the difference of single ablation outcomes between long-standing persistent and paroxysmal AF will be gradually reduced. Finally, the discrepancy between long-standing persistent and persistent AF patients (only 25% of whom underwent a repeat ablation) does not corroborate lower need for repeat ablation in the latter group. In fact, ablation of persistent AF was the least effective, and appropriate repeat ablation was not indicated for other reasons (see below).

4.3. Long-term outcome

Best long-term outcome was achieved in patients with long-standing persistent AF. Although the potential of extensive/repeat ablation for favorable long-term rhythm control in persistent AF types is high [19], the outcome of this study is rather unexpected [3,5,20,21]. It is likely that the extent of initial ablation and greater number of repeat ablations can effectively abolish even very complex arrhythmogenic sources. On the other hand, PV isolation for paroxysmal AF is more susceptible to missing possible (and not infrequent) extra-PV sources, and if repeat ablation concentrates only on PVs again and does not seek alternative sources, ablation failure and multiple repeat ablations may be at stake. In this respect, only 1% of long-standing persistent AF patients, but 2% of paroxysmal AF patients underwent four ablation procedures.

Obvious discrepancy between worse arrhythmia-free survival and, on the contrary, slightly better final SR maintenance in the group of long-standing persistent AF has a possible explanation. Following ablation of paroxysmal AF, recurrences of paroxysmal arrhythmia usually emerged from unaffected or recovered ectopic focus. First AF/AT recurrence largely heralded subsequent repeated recurrences (albeit possibly reduced in quantity and duration), while isolated AF/AT recurrences were very rare. On the other hand, after long-standing persistent AF ablation, isolated recurrences of persistent AT that never re-occurred after cardioversion and/or adjusted AAD medication were not infrequent.

There are, however, also several facts that may put the outcome of paroxysmal AF ablation into different light. First, accidental self-terminating AF/AT episodes in the paroxysmal AF group were tolerated in some patients as a clinical improvement. On the contrary, rare arrhythmia episodes after ablation of long-standing persistent AF were often indicated to timely repeat ablation (see also above). Second, by the end of the follow-up period, repeat ablations had been accomplished in a majority of eligible patients with long-standing persistent AF, while repeat ablation was successfully performed in some of the patients with paroxysmal AF after the follow-up had been closed. Finally, practically all ablation procedures for long-standing persistent AF were performed by the most experienced operator (note significantly shorter fluoroscopy times in this group), while learning curve of the beginning operators might have projected onto the outcomes of paroxysmal AF ablation.

Contradictory results in the persistent AF group also deserve several comments. The persistent AF patients represented a specific group in some aspects. They were significantly older, underwent fewest repeat procedures, and exhibited worst outcome. Interestingly, they also constituted the smallest group. It can be speculated that indication to catheter ablation of long-standing persistent AF was affected by the presumption that only younger patients would benefit. Many of these patients entered the category of long-standing persistent AF by exceeding the 12-month limit of persistent AF phase thanks to prior multiple pharmacological attempts to restore SR and the time spent on waiting list. On the other hand, older patients with persistent AF were frequently referred to catheter ablation at the stage of paroxysmal AF, but due to advanced arrhythmogenic substrate shortly developed persistent AF while awaiting ablation. It is also possible that the proportion of patients with persistent AF was under-valued because AF already persistent at the time of ablation was still counted as paroxysmal AF in some patients. Because these patients, based on the primary reference, were often approached as patients with paroxysmal AF, the need to enhance procedure extent and endpoints beyond PV isolation could be underestimated, or operators less experienced in extensive ablation were assigned to perform the procedure. As a result, the outcome of persistent AF ablation was not optimal. Simultaneously, the finding of advanced arrhythmogenic substrate together with older age might discourage both physicians and patients from repeat ablation.

5. Conclusion

Catheter ablation restored stable SR, and reduced the use of antiarrhythmic drugs and anticoagulation in a majority of patients. Patients with persistent AF types underwent more
extensive initial ablation. Patients with long-standing persistent AF experienced best long-term outcome likely as a consequence of higher number of repeat ablation procedures.

REFERENCES


